These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11365477)

  • 1. Efavirenz's complications.
    GMHC Treat Issues; 1998 May; 12(5):6. PubMed ID: 11365477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efavirenz and Fortovase.
    Baker R
    BETA; 1998 Jul; ():9. PubMed ID: 11365572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible fatal interaction between protease inhibitors and methamphetamine.
    Hales G; Roth N; Smith D
    Antivir Ther; 2000 Mar; 5(1):19. PubMed ID: 10846588
    [No Abstract]   [Full Text] [Related]  

  • 4. Delavirdine/protease inhibitor interactions.
    Gilden D
    GMHC Treat Issues; 1996 Sep; 10(9):11-2. PubMed ID: 11363839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA notifications. Potential serious effect of combination saquinavir-ritonavir.
    AIDS Alert; 2010 Apr; 25(4):45-6. PubMed ID: 20564774
    [No Abstract]   [Full Text] [Related]  

  • 6. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
    Manfredi R; Chiodo F
    J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ritonavir and saquinavir combination: 12-week data at ICAAC.
    James JS
    AIDS Treat News; 1996 Oct; (No 256):3. PubMed ID: 11363880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The medical merry-go-round: drugs for 1998 are new but not novel.
    Gilden D
    GMHC Treat Issues; 1997-1998 Winter; 12(1):18-25. PubMed ID: 11364984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fortovase approved: new saquinavir formulation.
    James JS
    AIDS Treat News; 1997 Nov; (No 283):1. PubMed ID: 11364907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New formulation of saquinavir (Fortovase) is more effective.
    Tam CW
    Fac Notes (New Orleans La); 1998; 10(2):11. PubMed ID: 11365126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-HIV drugs.
    De Clercq E
    Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efavirenz (Sustiva) receives FDA approval. Food and Drug Administration.
    Proj Inf Perspect; 1998 Dec; (26):11. PubMed ID: 11366487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New anti-HIV drugs in development.
    Proj Inf Perspect; 1999 Sep; (28):4-8. PubMed ID: 11367365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
    Cameron DW; Becker S; King MS; da Silva B; Klein C; Tokimoto D; Foit C; Calhoun D; Bernstein B; Hanna GJ
    J Antimicrob Chemother; 2007 May; 59(5):957-63. PubMed ID: 17350990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.